摘要
目的:探讨多西紫杉醇联合替吉奥胶囊治疗晚期食管胃交界腺癌的临床疗效和不良反应。方法:2009年1月—2011年1月经病理学确诊的58例晚期食管胃交界腺癌患者接受多西紫杉醇联合替吉奥胶囊治疗:多西紫杉醇35mg/m2静脉注射d1和d8,替吉奥胶囊胶囊每天70mg/m2d1～14,每3周为1个化疗周期。每2个化疗周期评价近期疗效。每个化疗周期后评价不良反应。对所有患者进行随访,评估生存情况。结果:58例患者均可评价疗效,其中完全缓解5例(8.6%)、部分缓解21例(36.2%),疾病稳定18例(31.0%),疾病进展14例(24.1%),有效率为44.8%(26/58)。中位TTP为8.0个月,MST为10.5个月。主要不良反应包括骨髓抑制、口腔炎、手足综合征和胃肠不良反应等。Ⅲ～Ⅳ级中性粒细胞减少发生率为25.9%(15/58)。结论:多西紫杉醇联合替吉奥胶囊治疗晚期食管胃交界腺癌的近期疗效较好,不良反应可以耐受。
Objective： To evaluate the efficacy and toxicity of docetaxel combined with tegafur, gimeracil and oteracil potassium （S-1） capsules in the treatment of patients with advanced adenocarcinoma of esophagogastric junction （AEG）. Methods： Fifty-eight patients with advanced AEG were recruited in this study between January 2009 and January 2011. All patients were treated with chemotherapy of docetaxel （35 mg.m-2.d-1 on d 1 and d 8; intravenous injection） combined with S-1 capsule （70 mg/m2 daily for 14 days）. The chemotherapy cycle was repeated every 21 days. The short- term response and the toxicity were evaluated every two cycles and one cycle, respectively. The follow-up examinations were performed in all patients, and the survival was calculated. Results： Of the 58 patients, there were 5 patients （8.6%）with complete response, 21 patients （36.2%）with partial response, 18 patients （31.0%） with stable disease, and 14 patients （24.1%） with progressive disease. The total response rate was 44.8% （26/58）. The median time to progression was 8.0 months, and the median survival time was 10.5 months. The major toxicities included leucopenia, stomatitis, hand-foot syndrome and adverse reactions of gastrointestinal tract. The rate of grade Ⅲ-Ⅳ leucopenia was 25.9% （15/58）. Conclusion： Docetaxel combined with S-1 capsule is effective and tolerable in the treatment of patients with advanced AEG.
出处
《肿瘤》
CAS
CSCD
北大核心
2011年第12期1111-1115,共5页
Tumor
关键词
食管胃交界腺癌
多西紫杉醇
替吉奥胶囊
抗肿瘤联合化疗方案
Adenocarcinoma of esophagogastric junction
Docetaxel
Tegafur, gimeracil and oteracil potassium capsule
Antineoplastic combined chemotherapy protocols
